Uncategorized

Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics

Astellas Venture Management LLC, a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission BioCapital BioLabs, a life-science incubator, announced TippingPoint Biosciences and Altay Therapeutics as the winners of the Astellas-sponsored “Future Innovator Prize” at MBC BioLabs.

Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics Read More »

Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® ‘s Seventh Indication and BYVASDA®’s Eighth Indication

Innovent Biologics, Inc. announces that, the National Reimbursement Drug List has been updated to renew and include the seventh indication of PD-1 inhibitor TYVYT® in negotiation list, and include the eighth indication of BYVASDA® in general list.

Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® ‘s Seventh Indication and BYVASDA®’s Eighth Indication Read More »

Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List

Zai Lab Limited announced that the 2023 National Reimbursement Drug List released by China’s National Healthcare Security Administration has been updated to include the following medicines and indications.

Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List Read More »

Scroll to Top